Biocon concludes 10% stake sale in Syngene

13 Jan 2015 Evaluate

Biocon has completed sale of 10% stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company. In September, the company had announced that Mauritius-based private equity fund Silver Leaf Oak would acquire 10% stake in its research services arm Syngene International for Rs 380 crore from Biocon Research (BRL), a wholly-owned subsidiary of the Bangalore-based firm.

The deal had put the entire valuation of Syngene International, a wholly-owned subsidiary of Biocon, at Rs 3,800 crore.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

 

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×